The therapeutic management of IBD often includes pharmacological agents (e.g., anti-TNF-α agents) that target these cytokines directly, aiming to reduce their concentration and, consequently, the inflammatory response (47). The gene discussed is TNF; the disease is inflammatory bowel disease.